Verona_Pharma_Dark_medium.jpg
Issue of Shares
September 19, 2017 07:53 ET | Verona Pharma plc
UK DISCLOSURE, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Issue of Shares...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)
September 07, 2017 02:00 ET | Verona Pharma plc
Achieved significant and clinically meaningful additional improvement in peak lung function and faster onset-of-action when added to tiotropium Demonstrated statistical significance across all...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Appoints Stifel as Nominated Adviser
September 01, 2017 02:00 ET | Verona Pharma plc
UK DISCLOSURE, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma Appoints Stifel as Nominated Adviser ...
Verona_Pharma_Dark_medium.jpg
PDMR Dealing
August 21, 2017 05:33 ET | Verona Pharma plc
LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona_Pharma_Dark_medium.jpg
Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development Update
August 08, 2017 02:00 ET | Verona Pharma plc
Completed US IPO Continues to advance lead candidate RPL554 with four clinical trials commenced LONDON, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update
August 02, 2017 11:00 ET | Verona Pharma plc
LONDON, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare Conference
August 01, 2017 07:00 ET | Verona Pharma plc
LONDON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment
July 26, 2017 02:00 ET | Verona Pharma plc
LONDON, July 26, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe
June 27, 2017 02:00 ET | Verona Pharma plc
LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory Affairs
June 22, 2017 07:00 ET | Verona Pharma plc
LONDON, June 22, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...